Seismic wave propagation around subsurface igneous sill complexes

Acknowledgements This work was undertaken during O.G.S’s PhD at Durham University, funded by Eni through the Volcanic Margins Research Consortium (Phase 2). Seismic modelling was performed using the open source SOFI2D (Bohlen 2002) and post-processed using Seismic Un*x (Stockwell & Cohen 2012). Figures were prepared using the open source Generic Mapping Tools (GMT) (Wessel & Smith W. H. F. 1998) and Seismic Un*x. Zoeppritz amplitude coefficients were calculated using the CREWES Matlab toolbox of the University of Calgary (Margrave and Lamoureux 2019). This work made use of the facilities of the Hamilton HPC Service of Durham UniversityPeer reviewe

Cylindrical, periodic surface lattice — theory, dispersion analysis, and experiment

A two-dimensional surface lattice of cylindrical topology obtained via perturbing the inner surface of a cylinder is considered. Periodic perturbations of the surface lead to observation of high-impedance, dielectric-like media and resonant coupling of surface and non-propagating volume fields. This allows synthesis of tailored-for-purpose "coating" material with dispersion suitable, for instance, to mediate a Cherenkov type interaction. An analytical model of the lattice is discussed and coupled-wave equations are derived. Variations of the lattice dispersive properties with variation of parameters are shown, illustrating the tailoring of the structure's electromagnetic properties. Experimental results are presented showing agreement with the theoretical model

Evaluasi Program Pembelajaran Bahasa Inggris

The aims of this research were to evaluate English learning in context, input, process, product. This research was an evaluation research. The sources of the research were students of English for Children class at English Smart Bandar Jaya. The data was collected through observation, test, and documentation which was analyzed descriptive quantitative. The conclusions in this research were : 1) the of context value of sub component at the pre-condition is fair, the input value of component sub component infrastructure,human resources and curriculum is poor, the result of process component sub component of planning and english learning implementation is fair, and the product component value in the learning result of the students is fair, and 2) the recommendation of this research,the general manager needs to observe and change the curriculum for a better future, then provide laboratory room for listening, the teachers should make a lesson plan based on the syllabus for each competency.Penelitian ini bertujuan untuk mengevaluasi pembelajaran Bahasa Inggris pada komponen context, input, process, product. Penelitian ini merupakan penelitian evaluasi. Sumber penelitian adalah pembelajar kelas English for Children di English Smart Bandar Jaya. Data dikumpulkan dengan observasi, tes dan dokumentasi kemudian dianalisis secara deskriptif kuantitatif. Kesimpulan dalam penelitian ini : 1) nilai context sub komponen kondisi awal lembaga cukup, nilai input sub komponen fasilitas sarana prasarana, tenaga pendidik dan kurikulum cukup, nilai process sub komponen perencanaan dan pelaksanaan pembelajaran bahasa Inggris kurang, dan nilai komponen product pada hasil belajar pembelajar cukup, dan 2) rekomendasi penelitian ini, kepala lembaga perlu meninjau atau mengubah kurikulum lembaga untuk pembaruan ke arah yang lebih baik, disediakan ruang laboratorium untuk menunjang pembelajaran listening, tentor harus membuat lesson plan yang disusun berdasarkan silabus unit kompetensi

National trends in heart failure mortality in men and women, United Kingdom, 2000–2017

Aims: To understand gender differences in the prognosis of women and men with heart failure, we compared mortality, cause of death and survival trends over time. Methods and results: We analysed UK primary care data for 26 725 women and 29 234 men over age 45 years with a new diagnosis of heart failure between 1 January 2000 and 31 December 2017 using the Clinical Practice Research Datalink, inpatient Hospital Episode Statistics and the Office for National Statistics death registry. Age-specific overall survival and cause-specific mortality rates were calculated by gender and year. During the study period 15 084 women and 15 822 men with heart failure died. Women were on average 5 years older at diagnosis (79.6 vs. 74.8 years). Median survival was lower in women compared to men (3.99 vs. 4.47 years), but women had a 14% age-adjusted lower risk of all-cause mortality [hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.84–0.88]. Heart failure was equally likely to be cause of death in women and men (HR 1.03, 95% CI 0.96–1.12). There were modest improvements in survival for both genders, but these were greater in men. The reduction in mortality risk in women was greatest for those diagnosed in the community (HR 0.83, 95% CI 0.80–0.85). Conclusions: Women are diagnosed with heart failure older than men but have a better age-adjusted prognosis. Survival gains were less in women over the last two decades. Addressing gender differences in heart failure diagnostic and treatment pathways should be a clinical and research priority.</p

Plakophilin 2: a critical scaffold for PKCα that regulates intercellular junction assembly

Plakophilins (PKPs) are armadillo family members related to the classical cadherin-associated protein p120ctn. PKPs localize to the cytoplasmic plaque of intercellular junctions and participate in linking the intermediate filament (IF)-binding protein desmoplakin (DP) to desmosomal cadherins. In response to cell–cell contact, PKP2 associates with DP in plaque precursors that form in the cytoplasm and translocate to nascent desmosomes. Here, we provide evidence that PKP2 governs DP assembly dynamics by scaffolding a DP–PKP2–protein kinase Cα (PKCα) complex, which is disrupted by PKP2 knockdown. The behavior of a phosphorylation-deficient DP mutant that associates more tightly with IF is mimicked by PKP2 and PKCα knockdown and PKC pharmacological inhibition, all of which impair junction assembly. PKP2 knockdown is accompanied by increased phosphorylation of PKC substrates, raising the possibility that global alterations in PKC signaling may contribute to pathogenesis of congenital defects caused by PKP2 deficiency

Low-dose spironolactone and cardiovascular outcomes in moderate stage Chronic Kidney Disease:a randomised controlled trial

Chronic kidney disease (CKD) is associated with substantial risk of progression to end stage renal disease and vascular events. The non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardio-renal protection for people with CKD and diabetes, but there is uncertainty if the steroidal MRA, spironolactone, provides the same protection. In this prospective, randomised, open, blinded endpoint (PROBE) trial we assessed the effectiveness of 25mg spironolactone in addition to usual care or usual care alone for reducing cardiovascular outcomes in stage 3b CKD among an older community cohort (mean age 74.8 years, standard deviation 8.1). We recruited 1,434 adults from English primary care, of whom 1,372 (96%) were included in the primary analysis. The primary outcome was time from randomisation until the first occurrence of; death, hospitalisation for heart disease, stroke, heart failure, transient ischaemic attack or peripheral arterial disease, or first onset of any condition listed not present at baseline. Across three years of follow-up, the primary endpoint occurred in 113/677 participants randomised to spironolactone (16.7%) and 111/695 randomised to usual care (16.0%) with no significant difference between groups (hazard ratio 1.05, 95%CI:0.81-1.37). Two-thirds of participants randomised to spironolactone stopped treatment within six months, predominantly because they met pre-specified safety stop criteria. The most common reason for stopping spironolactone was a decrease in the estimated glomerular filtration rate that met pre-specified stop criteria (n=239, 35.4%), followed by participants being withdrawn due to treatment side-effects (n=128, 18.9%) and hyperkalaemia (n=54, 8.0%). In conclusion, we found that spironolactone was frequently discontinued due to safety concerns, with no evidence that it reduced cardiovascular outcomes in people with stage 3b CKD. Spironolactone should not be used for people with stage 3b CKD without another explicit treatment indication. ClinicalTrials.gov registration: ISRCTN44522369.<br/

Low-dose spironolactone and cardiovascular outcomes in moderate stage Chronic Kidney Disease:a randomised controlled trial

Chronic kidney disease (CKD) is associated with substantial risk of progression to end stage renal disease and vascular events. The non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardio-renal protection for people with CKD and diabetes, but there is uncertainty if the steroidal MRA, spironolactone, provides the same protection. In this prospective, randomised, open, blinded endpoint (PROBE) trial we assessed the effectiveness of 25mg spironolactone in addition to usual care or usual care alone for reducing cardiovascular outcomes in stage 3b CKD among an older community cohort (mean age 74.8 years, standard deviation 8.1). We recruited 1,434 adults from English primary care, of whom 1,372 (96%) were included in the primary analysis. The primary outcome was time from randomisation until the first occurrence of; death, hospitalisation for heart disease, stroke, heart failure, transient ischaemic attack or peripheral arterial disease, or first onset of any condition listed not present at baseline. Across three years of follow-up, the primary endpoint occurred in 113/677 participants randomised to spironolactone (16.7%) and 111/695 randomised to usual care (16.0%) with no significant difference between groups (hazard ratio 1.05, 95%CI:0.81-1.37). Two-thirds of participants randomised to spironolactone stopped treatment within six months, predominantly because they met pre-specified safety stop criteria. The most common reason for stopping spironolactone was a decrease in the estimated glomerular filtration rate that met pre-specified stop criteria (n=239, 35.4%), followed by participants being withdrawn due to treatment side-effects (n=128, 18.9%) and hyperkalaemia (n=54, 8.0%). In conclusion, we found that spironolactone was frequently discontinued due to safety concerns, with no evidence that it reduced cardiovascular outcomes in people with stage 3b CKD. Spironolactone should not be used for people with stage 3b CKD without another explicit treatment indication. ClinicalTrials.gov registration: ISRCTN44522369.<br/

Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017:population based cohort study

Objectives To report reliable estimates of short term and long term survival rates for people with a diagnosis of heart failure and to assess trends over time by year of diagnosis, hospital admission, and socioeconomic group. Design Population based cohort study. Setting Primary care, United Kingdom. Participants Primary care data for 55 959 patients aged 45 and overwith a new diagnosis of heart failure and 278 679 age and sex matched controls in the Clinical Practice Research Datalink from 1 January 2000 to 31 December 2017 and linked to inpatient Hospital Episode Statistics and Office for National Statistics mortality data. Main outcome measures Survival rates at one, five, and 10 years and cause of death for people with and without heart failure; and temporal trends in survival by year of diagnosis, hospital admission, and socioeconomic group. Results Overall, one, five, and 10 year survival rates increased by 6.6% (from 74.2% in 2000 to 80.8% in 2016), 7.2% (from 41.0% in 2000 to 48.2% in 2012), and 6.4% (from 19.8% in 2000 to 26.2% in 2007), respectively. There were 30 906 deaths in the heart failure group over the study period. Heart failure was listed on the death certificate in 13 093 (42.4%) of these patients, and in 2237 (7.2%) it was the primary cause of death. Improvement in survival was greater for patients not requiring admission to hospital around the time of diagnosis (median difference 2.4 years; 5.3 v 2.9 years, P<0.001). There was a deprivation gap in median survival of 2.4 years between people who were least deprived and those who were most deprived (11.1 v 8.7 years, P<0.001). Conclusions Survival after a diagnosis of heart failure has shown only modest improvement in the 21st century and lags behind other serious conditions, such as cancer. New strategies to achieve timely diagnosis and treatment initiation in primary care for all socioeconomic groups should be a priority for future research and policy

Research priorities in advanced heart failure: James Lind alliance priority setting partnership.

OBJECTIVE: To determine research priorities in advanced heart failure (HF) for patients, carers and healthcare professionals. METHODS: Priority setting partnership using the systematic James Lind Alliance method for ranking and setting research priorities. An initial open survey of patients, carers and healthcare professionals identified respondents' questions, which were categorised to produce a list of summary research questions; questions already answered in existing literature were removed. In a second survey of patients, carers and healthcare professionals, respondents ranked the summary research questions in order of priority. The top 25 unanswered research priorities were then considered at a face-to-face workshop using nominal group technique to agree on a 'top 10'. RESULTS: 192 respondents submitted 489 responses each containing one or more research uncertainty. Out-of-scope questions (35) were removed, and collating the responses produced 80 summary questions. Questions already answered in the literature (15) were removed. In the second survey, 65 questions were ranked by 128 respondents. The top 10 priorities were developed at a consensus meeting of stakeholders and included a focus on quality of life, psychological support, the impact on carers, role of the charity sector and managing prognostic uncertainty. Ranked priorities by physicians and patients were remarkably divergent. CONCLUSIONS: Engaging stakeholders in setting research priorities led to a novel set of research questions that might not have otherwise been considered. These priorities can be used by researchers and funders to direct future research towards the areas which matter most to people living with advanced HF